Type: Protein-based coronavirus vaccine
Type: COVID-19 S-Trimer vaccine candidate, a protein-based coronavirus vaccine, in combination with GSK’s pandemic adjuvant system.
Status: GSK said June 19 that the vaccine it is co-developing with Clover had advanced into human clinical trials with the launch of a Phase I trial (NCT04405908) designed to assess SCB-2019. GSK cited “promising” preclinical results showing the beneficial effect of GSKs pandemic adjuvant for SCB-2019, with “high” neutralizing antibody levels elicited in multiple animal species. GSK offered no specifics in its announcement.
Preliminary safety and immunogenicity results for the Phase I study are expected in August. In parallel, Clover and GSK said, they are planning a global Phase IIb/III vaccine efficacy trial, with a launch set for later in 2020.
GSK agreed to provide Clover with its pandemic adjuvant system for further evaluation of S-Trimer in preclinical studies, the companies said in February, under a research collaboration whose value was not disclosed. GSK reasons that its adjuvant can reduce the amount of protein required per dose, allowing more vaccine doses to be produced—while Clover could rapidly scale-up and produce large-quantities of a new coronavirus vaccine since it has one of the largest in-house, commercial-scale cGMP biomanufacturing capabilities in China.
On March 25, GSK said that Clover was one of five partner companies and research groups worldwide with which GSK is collaborating on COVID-19 vaccines using GSK’s vaccine adjuvant technology. GSK said it expected data to be reported from the collaborations over the next three months.
GSK also said it was donating $10 million to The COVID-19 Solidarity Response Fund, created by the UN Foundation and WHO, to support WHO and partners to prevent, detect, and manage the pandemic.
“GSK is the world leader in vaccines, and partnering with them significantly boosts our hopes of both the timely development of a vaccine, and the capability to produce it in large enough quantities necessary to curb the coronavirus outbreak,” said Michael Breen, director, Infectious Diseases, Pharma at GlobalData.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: